

RECEIVED
CENTRAL FAX CENTER

JUN 01 2006

FACSIMILE TRANSMISSION

TO U.S. PATENT AND TRADEMARK OFFICE

DATE: June 01, 2006
FROM/ATTORNEY: Robyn Adams
FIRM: ZymoGenetics, Inc.
PAGES, INCLUDING COVERSHEET: 4
PHONE NUMBER: (206) 442-6752

TO EXAMINER: Landsman, R.
ART UNIT: 1647
SERIAL NUMBER: 10/733,597
FAX/TELECOPIER NUMBER: (571) 273-8300
COMMENTS:

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1066 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.

RECEIVED
CENTRAL FAX CENTER

JUN 01 2006

PATENT APPLICATION
File No: 00-34D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : James L. Holloway, Philippa J. Webster, Edward C. Thayer
Serial No. : 10/733,397
Group Art Unit : 1647
Examiner : Landsman, R.
Filed : December 11, 2003
For : MAMMALIAN GLYCOPROTEIN HORMONE-I

CERTIFICATE OF TRANSMISSION OR MAILING UNDER 37 CFR 1.8(a)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence, comprising:

1. Response to Restriction Requirement (2 pages)
2. Fax Cover Sheet

is being facsimile transmitted to the USPTO to facsimile number 571-273-8300 or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on June 1, 2006.

Nicole Hart



RECEIVED
CENTRAL FAX CENTER

JUN 01 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : James L. Holloway, Philippa J. Webster, Edward C. Thayer
Serial No. : 10/733,597
Filed : December 11, 2003
For : MAMMALIAN GLYCOPROTEIN HORMONE-1
Examiner : Landsman, R.
Art Unit : 1647
Docket No. : 00-34D1
Date : June 1, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

The Restriction Requirement mailed May 1, 2006, has been received and reviewed.

The Office Action sets forth a restriction requirement under 35 USC §121.

Applicants were requested to elect one of five designated groups as briefly noted below:

- I. Claim 1, drawn to polynucleotide, classified in class 536, subclass 23.5.
- II. Claims 2 and 5, drawn to a protein and a pharmaceutical composition, classified in class 530, subclass 350.
- III. Claim 3, drawn to an antibody of SEQ ID NO:2, classified in class 530, subclass 387.1.
- IV. Claim 4, drawn to a method of treating hyperthyroidism by administering a polypeptide, classified in class 514, subclass 2.
- V. Claim 6, drawn to the use of a polypeptide for making a medicament, classified in class 424, subclass 400.

Response to Restriction Requirement
Serial No.: 10/733,597

Page 2 of 2

In response to the Requirement for Restriction Election, Applicants elect Group III, claim 3, drawn to an antibody of SEQ ID NO:2, classified in class 530, subclass 387.1.

The Office has required Applicants to select one SEQ ID NO to be searched along with the elected invention. Applicants respectfully traverse this requirement. As clearly taught in the specification, the polypeptides of SEQ ID NO:s 2, 9, 10, 11, 12, 13, and 14 are all directed to the same amino acid sequence. For example, on page 3, lines 2-3, the specification teaches that human Zlu1 is represented by SEQ ID NO:s 1&2. SEQ ID NO:1 is the polynucleotide sequence, and SEQ ID NO:2 is the polypeptide sequence. Additionally, also on page 3, lines 7-9, the mature sequence is comprised of the polypeptide extending from amino acid residue 25, an alanine, to and including amino acid residue 130, an isoleucine, also represented by SEQ ID NO:9. Further, on page 52, lines 21-25, the specification teaches that the amino acid sequences of SEQ ID NO:2, *including* SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14 would provide suitable antigenic peptides. Thus, the SEQ ID NO:s of claims 2 and 5 are all directed to the same amino acid sequence and do not pose a serious burden for searching. In order to fully respond to the Election/Restriction, however, Applicants select SEQ ID NO:9.

Early reconsideration and allowance of the pending claims under examination are respectfully requested. If the Examiner believes that a telephone interview would expedite prosecution of the above-identified patent application, please call the undersigned at (206) 442-6752.

Respectfully Submitted,



Robyn Adams
Registration No. 44,495

Customer No. 10117
ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle, Washington 98102